Market Research Report
In-Vitro Diagnostic Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)
|Published by||Mordor Intelligence Pvt Ltd||Product code||390830|
|Published||Content info||115 Pages
Delivery time: 2-3 business days
|In-Vitro Diagnostic Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)|
|Published: February 1, 2021||Content info: 115 Pages||
The global In-Vitro Diagnostics market is valued at approximately USD 68,410 million in 2020 and is expected to witness a revenue of USD 91,250 million in 2026, with a CAGR of 4.90% over the forecast period.
The COVID-19 pandemic has turned the spotlight on the In-Vitro Diagnostics since there is an increasing demand for the IVD kits and reagents for the rapid and accurate diagnosis of SARS-CoV2 virus infection among the global population. The outbreak of COVID-19 is expected to positively impact the market studied, as in-vitro diagnostics involves testing of various biological samples. This is expected to aid the diagnosis of infectious diseases, such as COVID-19. Testing remains a crucial step in controlling the COVID-19 pandemic. As the number of COVID-19 cases is increasing across the world, governments of various countries are exploring the possibilities of allowing private laboratories to ramp up testing.
Also, the rapid launch of diagnostic kits for the diagnosis of COVID-19 by key players is driving the studied market during the pandemic. For instance, in March 2020, Qiagen launched QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe, and in April 2020, Altona Diagnostics launched CE-IVD marked RealStar SARS-CoV-2 RT-PCR Kit 1.0, an in vitro diagnostic test, based on real-time PCR technology, for the qualitative detection of lineage B-beta coronavirus (lineage B-BCoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific RNA. Additionally, in February 2020, the US FDA issued a new policy to expedite the availability of diagnostics. A public health emergency was determined, justifying the authorization of emergency use of in vitro diagnostics (IVDs) for the diagnosis of COVID-19. Thus, the global COVID-19 pandemic is expected to have a positive impact on the growth of the studied market.
The growth of the global IVD market can be attributed to the high prevalence of chronic and infectious diseases. According to the World Heart Federation 2018, coronary heart disease is the leading cause of death worldwide. An estimated 3.8 million men and 3.4 million women die each year from coronary heart disease. Besides, 80% of the deaths occur in low- and middle-income countries. The high incidence of chronic diseases increases the demand for huge diagnostic procedures, which in turn drives the studied market.
Additionally, the current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation of diagnostics that work at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR), and next-generation sequencing (NGS) in the IVD platform. Also, the increasing product launches with advanced features is expected to drive the studied market. For instance, in Jan 2020, SphingoTec GmbH launched its IB10 sphingotest penKid, a CE-IVD-marked point-of-care test for Proenkephalin, the biomarker that allows real-time assessment of kidney function with a simple blood test. Thus, given the aforementioned factors, the In-Vitro Diagnostic market is anticipated to propel over the forecast period.
Reagents are Expected to Hold Largest Market Share in the Product Segment
In the product segment of the In-Vitro Diagnostic market, the reagent is expected to witness the largest CAGR over the forecast period.
The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end-users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the life of the contract.
The COVID-19 is expected to significantly aid in the growth of the studied segment owing to the high requirement of reagents to meet the increasing diagnostics demand globally, for the diagnosis of COVID-19 infection.
Additionally, with the increasing burden of chronic diseases worldwide, the demand for in vitro diagnostics rises, which in turn surges the demand for reagents used in the various testing platforms. Also, the growing product launches in the market is expected to drive the market. For instance, in Nov 2019, Vidan Diagnostics launched B-Hydroxybutyrate 21FS Reagent for Beckman Coulter AU clinical chemistry systems. Thus, in view of the aforementioned factors, the reagent segment is expected to grow tremendously over the forecast period.
North America Dominates the Market and is Expected to Continue its Dominance in the Forecast Period
North America currently dominates the market for In-Vitro Diagnostic and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future owing to the well-established healthcare industry and rising prevalence of chronic diseases in the region. The United States holds the majority of the market in the North America region due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.
According to the American Cancer Society, in 2020, about 1.8 million new cancer cases are expected to be diagnosed and approximately 606,520 cancer deaths might occur in the United States. Moreover, people with chronic conditions are the most frequent users of healthcare facilities in the United States. They account for the majority of hospital admissions and prescriptions filling and thus, drive the growth of the studied market.
Also in February 2020, FDA issued its first Emergency Use Authorization to the Centers for Disease Control and Prevention (CDC), authorizing the use of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel for the presumptive qualitative detection of nucleic acid from Covid-19 samples in response to the COVID-19 pandemic. Hence, following this many in-vitro diagnostics received FDA's EUA, which is expected to impact the market growth in the region.
Additionally, the growing number of product launches in the region and high concentration of key players in North America acts as a major factor in driving the market. For instance, in May 2020, Bio-Rad Laboratories, Inc's SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). The SARS-CoV-2 Droplet Digital PCR (ddPCR) test runs on Bio-Rad's QX200 and QXDx ddPCR systems. Thus, given the aforementioned factors, the In-vitro diagnostic market is anticipated to grow significantly in North America over the forecast period.
The In-Vitro Diagnostic market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices. Companies like Thermo Fischer Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, and F. Hoffmann-La Roche AG. holds a substantial market share in the In-Vitro Diagnostic market. Additionally, the key players are involved in strategic alliances such as acquisitions, collaborations, and partnerships with companies that complement its product portfolio. For instance, in May 2020, Becton Dickinson and Company completed the acquisition of NAT Diagnostics to expand its Point-of-Care testing for infectious disease portfolio.